Metastatic cancer is a cagey adversary, a shape- and form-changing disease that can be understood only by following its dynamics at a cellular level. Because most tests are based upon fixed assumptions of what cancer looks like, however, they come up short. For that reason, Epic Sciences chose a research road less traveled, a bias-free approach that looks at all the cells in a non-invasive blood sample, and thus sees those rare cells that others miss.
Every cancer is as unique as the person who carries it. So the tests that diagnose and monitor the illness must be eminently personal, proven and precise.
If you can’t see the problem, you can’t solve it.
Maximizing a revolutionary component: Certainty.
Epic’s new AR-V7 CTC liquid biopsy test is the first clinically proven predictive test for metastatic castration-resistant prostate cancer. This test requires but a simple blood draw and is unambiguous, giving doctors a clearer picture of a patient's metastatic disease, thus allowing them to proceed with confidence and certainty while sparing patients the anxiety associated with the uncertainty of an uninformed choice.
A bias-free vision of cancer research.
At Epic Sciences, we develop clinical solutions that accelerate drug development and provide valuable insights into the dynamics of cancer growth, evolution and heterogeneity. Our AR-V7 CTC test, for example, has demonstrated predictive clinical utility for prostate cancer. It’s but one example of our dedication to the development of proven tests to guide therapy selection across the most impactful drug classes in oncology.
Video - New test extending lives of advanced prostate cancer patients
Bryce Olson discusses the Oncotype DX® AR-V7 Nucleus Detect™ test, developed by Epic Sciences and commercially available through Genomic Health, with ABC 10 News. The test determines which men with late-stage metastatic prostate cancer will benefit from AR-targeted therapy or chemotherapy.
Blood Test May Identify Cancer Patients Who Respond to PSMA-Targeted Therapies
San Diego, CLP Magazine — In a study sponsored by Epic Sciences, San Diego, in partnership with Memorial Sloan Kettering Cancer Center, researchers have demonstrated that a liquid biopsy blood test may be used before treatment is initiated in clinical trials to find patients who are likely to benefit from therapies targeting prostate-specific membrane antigen.
Metastatic Breast Cancer Clinical Trial Forged by Epic Sciences, Canadian Consortium
New York, GenomeWeb – Epic Sciences announced today that it has partnered with four major Canadian breast cancer centers on a clinical trial to see if the firm's blood test can be used to predict the risk of late recurrence of metastatic breast cancer in female patients.
Epic Sciences, Genomic Health Get Medicare LCD for Prostate Cancer Diagnostic
San Diego, Clinical OMICs – Epic Sciences and Genomic Health announced that Medicare Administrative Contractor Palmetto GBA, has issued a positive final local coverage determination (LCD) for the Oncotype DX AR-V7 Nucleus Detect test. The final LCD recommends Medicare coverage effective December 10, 2018.